Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.11 -0.21 (-0.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Should you consider NASDAQ:CPRX for growth investing?
Exploring growth characteristics of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Neurocrine Biosciences Stock Sees RS Rating Upgrade
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:CPRX is a compelling option with its solid fundamentals.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:CPRX.
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s growth characteristics. 
Via Chartmill
Why NASDAQ:CPRX qualifies as a high growth stock.
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing? 
Via Chartmill
Is NASDAQ:CPRX on the Verge of a Major Breakout as a Strong Growth Stock?
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
NASDAQ:CPRX is showing good growth, while it is not too expensive.
NASDAQ:CPRX is showing good growth, while it is not too expensive. 
Via Chartmill
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
Don't overlook NASDAQ:CPRX—a stock with solid growth prospects and a reasonable valuation.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:CPRX remains undervalued.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals. 
Via Chartmill
NASDAQ:CPRX is an undervalued gem with solid fundamentals.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
A Peek at Catalyst Pharmaceuticals's Future Earnings
Via Benzinga
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
NASDAQ:CPRX, a growth stock which is not overvalued.
NASDAQ:CPRX is showing decent growth, but is still valued reasonably. 
Via Chartmill
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.